Advertisements



Do drug treatment facilities really lower property values? Finally, an answer

When it comes to rehab centers, many people think ‘not in my backyard.’.....»»

Category: topSource: marketwatchJan 11th, 2019

A major pillar of China"s economy has passed the "tipping point" and could slow further, analyst says

China Photos/Getty Images China started a shanty town renovation program in 2015 in an effort to drive home sales in lower-tier cities, helping lift the country's property values over the past few years. To calm the red-hot hous.....»»

Category: topSource: businessinsiderDec 6th, 2018

Eisai starts phase 3 trials for second Alzheimer"s drug after first"s failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab......»»

Category: topSource: reutersMar 22nd, 2019

There"s finally a drug for postpartum depression. Too bad it"s $34,000.

Brexanolone was designed to address an unmet medical need. It’s also complicated to use......»»

Category: topSource: moneycentralMar 21st, 2019

The Ratings Game: Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout

Shares of Sage Therapeutics Inc. rose 3% Wednesday morning after the company’s announcement Tuesday evening that the Food and Drug Administration had approved its drug for the treatment of postpartum depression......»»

Category: topSource: marketwatchMar 20th, 2019

FDA approves new treatment for postpartum depression

The FDA has approved biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the market and o.....»»

Category: topSource: bizjournalsMar 20th, 2019

FDA Approves First Drug Treatment for Postpartum Depression

But it requires an IV drip for 60 hours at a health care facility. The U.S. Food and Drug Administration (FDA) has approved a drug for the first time that aims at treating p.....»»

Category: europeSource: fortuneMar 20th, 2019

FDA approves first postpartum depression drug — it could help hundreds of thousands of new mothers

A new treatment for postpartum depression, called brexanolone, was approved by the Food and Drug Administration on Tuesday......»»

Category: topSource: marketwatchMar 20th, 2019

FDA approves Sage"s first-ever treatment for postpartum depression

The FDA has approved Cambridge biopharma Sage Therapeutics' first product, a drug that the company says will be the first product specifically designed to treat postpartum depression. Zulresso is Sage's (Nasdaq: SAGE) first product to reach the market.....»»

Category: topSource: bizjournalsMar 19th, 2019

Aluminum producer Hydro hit by cyber attack

Norsk Hydro, one of the world's largest producers of aluminum, was battling on Tuesday to contain a cyber attack which hit its production facilities, sending shares lower......»»

Category: topSource: reutersMar 19th, 2019

FDA is expected to approve a postpartum depression drug for the first time — it could help hundreds of thousands of new mothers

A new treatment for postpartum depression, called brexanolone, is expected to be approved by the Food and Drug Administration this month......»»

Category: topSource: marketwatchMar 16th, 2019

Fast-acting treatment for postpartum depression, if approved, could help hundreds of thousands of new mothers

A new treatment for postpartum depression, called brexanolone, is expected to be approved by the Food and Drug Administration this month......»»

Category: topSource: marketwatchMar 15th, 2019

Are GE"s Guidance Cuts Finally Over? Analysts Speak Up On Company"s Financial Update

General Electric Company (NYSE: GE) investors weren’t impressed by CEO Larry Culp’s pledge for transparency on Thursday, sending the stock lower on Friday. Latest Ratings.....»»

Category: blogSource: benzingaMar 15th, 2019

The Wall Street Journal: Adamis Pharma stock jumps after FDA agrees to review injectable opioid-overdose treatment

Adamis Pharmaceuticals Corp. said the U.S. Food and Drug Administration has accepted for review its New Drug Application for a naloxone injection product used to treat opioid overdoses......»»

Category: topSource: marketwatchMar 14th, 2019

Pfizer"s (PFE) Kidney Cancer Drug Combo Gets EMA"s Validation

Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of ad.....»»

Category: dealsSource: nytMar 12th, 2019

Stalled for years, massive Redwood City salt ponds where developer envisioned 12,000 homes could now see development

A long-controversial Bayside property in Redwood City could finally see new development after the U.S. Environmental Protection Agency cleared some regulatory restrictions. The EPA ruled that the former Cargill salt ponds are exempt from the Clean .....»»

Category: topSource: bizjournalsMar 12th, 2019

Bayer Submits Application in EU for Prostate Cancer Drug

Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resista.....»»

Category: dealsSource: nytMar 11th, 2019

Cannabis Watch: Cannabis stocks mixed as investors parse FDA’s latest comments on CBD regulation

Cannabis stocks were mostly lower on Friday, as investors and company executives continued to parse comments by the head of the U.S. Food and Drug Administration on the outlook for regulation of CBD......»»

Category: topSource: marketwatchMar 1st, 2019

Cannabis Watch: Cannabis stocks tumble as GW Pharma rallies after strong Epidiolex launch

GW Pharmaceuticals PLC shares were a standout among cannabis stocks Wednesday, after the company reported a strong start for Epidiolex, the first cannabis-based drug to win regulatory approval as a treatment for a severe form of childhood epilepsy......»»

Category: topSource: marketwatchFeb 27th, 2019

7 pharma execs just told Congress: Don"t expect the Trump administration"s newest drug pricing plan to lower all US drug prices yet

AP Photo/Pablo Martinez Monsivais The Trump administration has proposed getting rid of discounts called.....»»

Category: topSource: businessinsiderFeb 26th, 2019

Drug industry defense for high prices: Blame insurance companies

The industry contends it is trapped in a reimbursement system that has become badly distorted, one that rewards companies for jacking up list prices and then offering deep discounts to win favorable treatment by insurance plans......»»

Category: topSource: washpostFeb 25th, 2019